Literature DB >> 25292181

Atomoxetine prevents dexamethasone-induced skeletal muscle atrophy in mice.

Sean R Jesinkey1, Midhun C Korrapati1, Kyle A Rasbach1, Craig C Beeson1, Rick G Schnellmann2.   

Abstract

Skeletal muscle atrophy remains a clinical problem in numerous pathologic conditions. β2-Adrenergic receptor agonists, such as formoterol, can induce mitochondrial biogenesis (MB) to prevent such atrophy. Additionally, atomoxetine, an FDA-approved norepinephrine reuptake inhibitor, was positive in a cellular assay for MB. We used a mouse model of dexamethasone-induced skeletal muscle atrophy to investigate the potential role of atomoxetine and formoterol to prevent muscle mass loss. Mice were administered dexamethasone once daily in the presence or absence of formoterol (0.3 mg/kg), atomoxetine (0.1 mg/kg), or sterile saline. Animals were euthanized at 8, 16, and 24 hours or 8 days later. Gastrocnemius muscle weights, changes in mRNA and protein expression of peroxisome proliferator-activated receptor-γ coactivator-1 α (PGC-1α) isoforms, ATP synthase β, cytochrome c oxidase subunit I, NADH dehydrogenase (ubiquinone) 1 β subcomplex, 8, ND1, insulin-like growth factor 1 (IGF-1), myostatin, muscle Ring-finger protein-1 (muscle atrophy), phosphorylated forkhead box protein O 3a (p-FoxO3a), Akt, mammalian target of rapamycin (mTOR), and ribosomal protein S6 (rp-S6; muscle hypertrophy) in naive and muscle-atrophied mice were measured. Atomoxetine increased p-mTOR 24 hours after treatment in naïve mice, but did not change any other biomarkers. Formoterol robustly activated the PGC-1α-4-IGF1-Akt-mTOR-rp-S6 pathway and increased p-FoxO3a as early as 8 hours and repressed myostatin at 16 hours. In contrast to what was observed with acute treatment, chronic treatment (7 days) with atomoxetine increased p-Akt and p-FoxO3a, and sustained PGC-1α expression and skeletal muscle mass in dexamethasone-treated mice, in a manner comparable to formoterol. In conclusion, chronic treatment with a low dose of atomoxetine prevented dexamethasone-induced skeletal muscle wasting and supports a potential role in preventing muscle atrophy. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25292181      PMCID: PMC4244586          DOI: 10.1124/jpet.114.217380

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  43 in total

Review 1.  Autocrine and/or paracrine insulin-like growth factor-I activity in skeletal muscle.

Authors:  Gregory R Adams
Journal:  Clin Orthop Relat Res       Date:  2002-10       Impact factor: 4.176

Review 2.  Glucocorticoid-induced skeletal muscle atrophy.

Authors:  O Schakman; S Kalista; C Barbé; A Loumaye; J P Thissen
Journal:  Int J Biochem Cell Biol       Date:  2013-06-24       Impact factor: 5.085

3.  Facilitatory and inhibitory effects of selective norepinephrine reuptake inhibitors on hypogastric nerve-evoked urethral contractions in the cat: a prominent role of urethral beta-adrenergic receptors.

Authors:  J P Springer; B P Kropp; K B Thor
Journal:  J Urol       Date:  1994-08       Impact factor: 7.450

4.  β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis.

Authors:  Yuri K Peterson; Robert B Cameron; Lauren P Wills; Richard E Trager; Chris C Lindsey; Craig C Beeson; Rick G Schnellmann
Journal:  Bioorg Med Chem Lett       Date:  2013-07-31       Impact factor: 2.823

5.  Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscle.

Authors:  Gopal K R Soppa; Ryszard T Smolenski; Najma Latif; Ada H Y Yuen; Aalya Malik; Joanna Karbowska; Zdzislaw Kochan; Cesare M N Terracciano; Magdi H Yacoub
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-11-04       Impact factor: 4.733

6.  Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1.

Authors:  Hongmei Wang; Neil Kubica; Leif W Ellisen; Leonard S Jefferson; Scot R Kimball
Journal:  J Biol Chem       Date:  2006-10-30       Impact factor: 5.157

Review 7.  Regulation of muscle mass by myostatin.

Authors:  Se-Jin Lee
Journal:  Annu Rev Cell Dev Biol       Date:  2004       Impact factor: 13.827

8.  A PGC-1α isoform induced by resistance training regulates skeletal muscle hypertrophy.

Authors:  Jorge L Ruas; James P White; Rajesh R Rao; Sandra Kleiner; Kevin T Brannan; Brooke C Harrison; Nicholas P Greene; Jun Wu; Jennifer L Estall; Brian A Irving; Ian R Lanza; Kyle A Rasbach; Mitsuharu Okutsu; K Sreekumaran Nair; Zhen Yan; Leslie A Leinwand; Bruce M Spiegelman
Journal:  Cell       Date:  2012-12-07       Impact factor: 41.582

Review 9.  Muscle plasticity and β₂-adrenergic receptors: adaptive responses of β₂-adrenergic receptor expression to muscle hypertrophy and atrophy.

Authors:  Shogo Sato; Ken Shirato; Kaoru Tachiyashiki; Kazuhiko Imaizumi
Journal:  J Biomed Biotechnol       Date:  2011-11-15

Review 10.  Cellular and molecular mechanisms of muscle atrophy.

Authors:  Paolo Bonaldo; Marco Sandri
Journal:  Dis Model Mech       Date:  2013-01       Impact factor: 5.758

View more
  17 in total

Review 1.  Adrenoceptor regulation of the mechanistic target of rapamycin in muscle and adipose tissue.

Authors:  Ling Yeong Chia; Bronwyn A Evans; Saori Mukaida; Tore Bengtsson; Dana S Hutchinson; Masaaki Sato
Journal:  Br J Pharmacol       Date:  2019-04-07       Impact factor: 8.739

Review 2.  Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.

Authors:  Robert B Cameron; Craig C Beeson; Rick G Schnellmann
Journal:  J Med Chem       Date:  2016-09-27       Impact factor: 7.446

Review 3.  Mitochondrial-Based Therapeutics for the Treatment of Spinal Cord Injury: Mitochondrial Biogenesis as a Potential Pharmacological Target.

Authors:  Natalie E Scholpa; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2017-09-21       Impact factor: 4.030

4.  Tissue-Engineered Human Myobundle System as a Platform for Evaluation of Skeletal Muscle Injury Biomarkers.

Authors:  Alastair Khodabukus; Amulya Kaza; Jason Wang; Neel Prabhu; Richard Goldstein; Vishal S Vaidya; Nenad Bursac
Journal:  Toxicol Sci       Date:  2020-07-01       Impact factor: 4.849

5.  Pharmacological Stimulation of Mitochondrial Biogenesis Using the Food and Drug Administration-Approved β2-Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury.

Authors:  Natalie E Scholpa; Hannah Williams; Wenxue Wang; Daniel Corum; Aarti Narang; Stephen Tomlinson; Patrick G Sullivan; Alexander G Rabchevsky; Rick G Schnellmann
Journal:  J Neurotrauma       Date:  2018-11-16       Impact factor: 5.269

6.  β2-adrenergic receptor-mediated mitochondrial biogenesis improves skeletal muscle recovery following spinal cord injury.

Authors:  Natalie E Scholpa; Epiphani C Simmons; Douglas G Tilley; Rick G Schnellmann
Journal:  Exp Neurol       Date:  2019-09-13       Impact factor: 5.330

7.  MicroRNA351 targeting TRAF6 alleviates dexamethasone-induced myotube atrophy.

Authors:  Jiaying Qiu; Lingbin Wang; Ye Wang; Qiuyu Zhang; Wenjing Ma; Qingqing Fang; Hualin Sun; Fei Ding
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

8.  Identification of a KLF5-dependent program and drug development for skeletal muscle atrophy.

Authors:  Lin Liu; Hiroyuki Koike; Takehito Ono; Shinichiro Hayashi; Fujimi Kudo; Atsushi Kaneda; Hiroyuki Kagechika; Ichiro Manabe; Tomoki Nakashima; Yumiko Oishi
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-31       Impact factor: 11.205

9.  Dexamethasone and BCAA Failed to Modulate Muscle Mass and mTOR Signaling in GH-Deficient Rats.

Authors:  Hikaru Nishida; Ayaka Ikegami; Chiaki Kaneko; Hitomi Kakuma; Hisano Nishi; Noriko Tanaka; Michiko Aoyama; Makoto Usami; Yasuhiko Okimura
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

10.  Urinary mitochondrial DNA is a biomarker of mitochondrial disruption and renal dysfunction in acute kidney injury.

Authors:  Ryan M Whitaker; L Jay Stallons; Joshua E Kneff; Joseph L Alge; Jennifer L Harmon; Jennifer J Rahn; John M Arthur; Craig C Beeson; Sherine L Chan; Rick G Schnellmann
Journal:  Kidney Int       Date:  2015-08-19       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.